Analysts Predict 14% Upside For RWK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The Invesco S&P MidCap 400 Revenue ETF (RWK) has an implied analyst target price of $138.38, suggesting a potential upside of 13.81% from its current trading price of $121.59.
Individual Stock Upside Potential: Notable underlying holdings like Cleveland-Cliffs Inc, Neogen Corp, and Vail Resorts Inc show significant upside potential based on analyst targets, with expected increases of 30.50%, 22.16%, and 17.03% respectively.
Analyst Views on NEOG
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 9.870
Low
6.50
Averages
8.17
High
10.00
Current: 9.870
Low
6.50
Averages
8.17
High
10.00
About NEOG
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
